18 September 2020 : Original article
ABO-Incompatible Living Donor Liver Transplantation with Reduced Rituximab Dose: A Retrospective Analysis of 65 Patients – Can We Fast-Track Liver Transplant Surgery and Improve Long-Term Survival?
Shih-Chao Hsu123ABCDEF, Ashok Thorat13ABCEF, Long-Bin Jeng143ABCDEF*, Ping-Chun Li135ADF, Te-Hung Chen123BCF, Horng-Ren Yang123BDE, Kin-Shing Poon36DFDOI: 10.12659/AOT.923502
Ann Transplant 2020; 25:e923502
Table 1 General characteristics of study cohort.
Variables | Era III ABOi LDLT recipients (n=50) |
---|---|
Male: Female | 38: 12 |
Age (years) | 54±8 years (range, 32 to 67 years) |
HCV related ESLD | 3 |
HBV related ESLD | 5 |
HCC | 27 |
Others | 15 |
MELD score | 16±8 (range, 6–41) |
ABOi donation | |
A to O | 20 |
B to O | 15 |
A to B | 2 |
B to A | 2 |
AB to A | 8 |
AB to B | 3 |
Rituximab dose | 200 mg single dose |
LDLT performed within 5 days of rituximab | 7 |
DFPP sessions | 4 |
CD 19 B cell count | |
Pre-rituximab | 16±10.8 (range, 2.1–54.2) |
Pre-LDLT | 0.5 ± 1.0 (range, 0–6) |
Post-LDLT | 0.7 ± 1.1 (range, 0–6.4) |
Splenectomy | 1 |